Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years.
Saved in:
Main Authors: | Piero L Olliaro (Author), Annette C Kuesel (Author), Christine M Halleux (Author), Mark Sullivan (Author), John C Reeder (Author) |
---|---|
Format: | Book |
Published: |
Public Library of Science (PLoS),
2018-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A changing model for developing health products for poverty-related infectious diseases.
by: Piero L Olliaro, et al.
Published: (2015) -
Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decade.
by: Rianna Stefanakis, et al.
Published: (2012) -
Is the priority review voucher program stimulating new drug development for tropical diseases?
by: Kirk W Kerr, et al.
Published: (2018) -
Saving the tourism industry with staycation vouchers [version 1; peer review: 2 approved, 1 approved with reservations]
by: Marko Ogorevc, et al.
Published: (2020) -
Overview of drugs approved by the FDA in 2022
by: D. V. Kurkin, et al.
Published: (2023)